<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462069</url>
  </required_header>
  <id_info>
    <org_study_id>PDY15010</org_study_id>
    <secondary_id>2017-002309-36</secondary_id>
    <secondary_id>U1111-1186-2962</secondary_id>
    <nct_id>NCT03462069</nct_id>
  </id_info>
  <brief_title>Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group, 2-treatment Multiple Dose Study to Assess the Intestinal, Metabolic and Cardiovascular Effects of an 8 Weeks Treatment With Sotagliflozin QD as Compared With Empagliflozin Once a Day (QD) in Type 2 Diabetes Mellitus (T2DM) Patients With Mild to Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To compare the metabolic and gastrointestinal pharmacodynamic (PD) effects of an 8 weeks&#xD;
      treatment with sotagliflozin once daily (QD) to an 8 weeks treatment to empagliflozin QD in&#xD;
      mild or moderate hypertensive T2DM patients on a stable treatment regimen with metformin and&#xD;
      an angiotensin converting enzyme (ACE) inhibitor or Angiotensin Receptor Blocker (ARB) under&#xD;
      standardized diet conditions.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To compare the renal and cardiovascular PD effects of an 8 weeks treatment with&#xD;
           sotagliflozin QD to an 8 weeks treatment to empagliflozin QD in mild or moderate&#xD;
           hypertensive T2DM patients on a stable treatment regimen with metformin and an ACE&#xD;
           inhibitor or ARB.&#xD;
&#xD;
        -  To evaluate the safety and tolerability of an 8 weeks QD treatment with sotagliflozin or&#xD;
           empagliflozin in mild to moderate hypertensive T2DM patients on a stable treatment with&#xD;
           metformin and an ACE inhibitor or ARB.&#xD;
&#xD;
        -  To evaluate the pharmacokinetic (PK) profile of sotagliflozin in steady state&#xD;
           conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per patient is 70-105 days (for patients without drug washout/switch&#xD;
      period), and up to 175 days (for patients with drug washout/switch period), including 2-30&#xD;
      days of screening, 5 days of run-in period, 56 days of treatment period, and a 7-14 days of&#xD;
      follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Actual">April 18, 2019</completion_date>
  <primary_completion_date type="Actual">April 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of pharmacodynamic (PD) parameters in feces</measure>
    <time_frame>Baseline and on Day 55 and 56 (over 48 hours)</time_frame>
    <description>Change from baseline in fecal sodium excretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of pharmacodynamic (PD) parameters in feces</measure>
    <time_frame>Baseline and on Day 55 and 56 (over 48 hours)</time_frame>
    <description>Change from baseline in fecal short-chain fatty acids (SCFA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of pharmacodynamic (PD) parameters in feces</measure>
    <time_frame>Baseline and on Day 55 and 56 (over 48 hours)</time_frame>
    <description>Change from baseline in fecal pH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PD parameters in urine</measure>
    <time_frame>Baseline and on Day 56 (over 24 hours)</time_frame>
    <description>Change from baseline in 24-hour urinary glucose excretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PD parameters in urine</measure>
    <time_frame>Baseline and on Day 56 (over 24 hours)</time_frame>
    <description>Change from baseline in 24-hour sodium excretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PD parameters in blood</measure>
    <time_frame>Baseline and on Day 56</time_frame>
    <description>14 hour plasma glucose profile after standardized meals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PD parameters in blood</measure>
    <time_frame>Baseline and on Day 56</time_frame>
    <description>14 hour plasma glucagon-like peptide 1 (GLP-1) profile after standardized meals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting metabolic laboratory panel</measure>
    <time_frame>Baseline and on Day 56</time_frame>
    <description>Change from baseline in fasting plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory Blood Pressure Measurement (ABPM)</measure>
    <time_frame>Baseline and on days 54 until Day 56</time_frame>
    <description>Change from baseline in average 24h systolic arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular parameters</measure>
    <time_frame>Baseline and on Day 56</time_frame>
    <description>Change from baseline in plasma aldosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>Baseline and on Day 55</time_frame>
    <description>Change from baseline in carotid-femoral pulse wave velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Glucose Monitoring (CGM)</measure>
    <time_frame>Baseline, last 3 days of treatment</time_frame>
    <description>Change from baseline in average diurnal glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>Baseline and on Day 54</time_frame>
    <description>Change from baseline in left ventricular ejection fraction (LVEF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>Baseline and on Day 54</time_frame>
    <description>Change from baseline in left ventricular end-diastolic diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Volume Measurement</measure>
    <time_frame>Baseline and on Day 54</time_frame>
    <description>Change from baseline in plasma volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Over 15 weeks</time_frame>
    <description>Number of patients with reported adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic (PK) parameters: Cmax</measure>
    <time_frame>24 hours after last investigational medicinal product (IMP) administration</time_frame>
    <description>Sotagliflozin: maximum plasma concentration observed (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic (PK) parameters: Ctrough</measure>
    <time_frame>24 hours after last IMP administration</time_frame>
    <description>Sotagliflozin: plasma concentration observed before administration during repeated dosing (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic (PK) parameters: AUCtau</measure>
    <time_frame>24 hours after last IMP administration</time_frame>
    <description>Sotagliflozin: Area under the plasma concentration versus time curve calculated using the trapezoidal method over the dosing interval (AUCtau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic (PK) parameters: tmax</measure>
    <time_frame>24 hours after last IMP administration</time_frame>
    <description>Sotagliflozin: First time to reach Cmax (tmax)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Treatment A (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sotagliflozin 2 tablets administered once daily with 1 empagliflozin placebo capsule prior to the first meal of the day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B (Reference)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Empagliflozin 1 capsule administered once daily with 2 sotagliflozin placebo tablets prior to the first meal of the day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotagliflozin (SAR439954)</intervention_name>
    <description>Pharmaceutical form: tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>Treatment A (Test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>Treatment B (Reference)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Pharmaceutical form: capsule&#xD;
Route of administration: oral</description>
    <arm_group_label>Treatment B (Reference)</arm_group_label>
    <other_name>JardianceÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: capsule&#xD;
Route of administration: oral</description>
    <arm_group_label>Treatment A (Test)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Male or female patients with Type 2 Diabetes Mellitus (T2DM) (diagnosed at least 1&#xD;
             year before screening visit), between 18 and 74 years of age, inclusive, with:&#xD;
&#xD;
               -  Hypertension grades 1 or 2 as defined by the European Society of Hypertension&#xD;
                  (ESH)/European Society of Cardiology (ESC) at screening; systolic blood pressure&#xD;
                  (SBP) has to be in the range of 140-179 mmHg (after 10 minutes resting in supine&#xD;
                  position, measurement in triplicate with each measurement to be within this range&#xD;
                  at screening). If the blood pressure (BP) range is not met at screening, one&#xD;
                  repeat measurement at another occasion is allowed prior to inclusion into the&#xD;
                  study.&#xD;
&#xD;
               -  Glycated Haemoglobin A1c (HbA1c) at screening between 6.5% and 11%.&#xD;
&#xD;
          -  On a stable treatment with metformin, i.e., no change in dose regimen or in dose&#xD;
             levels in the last 3 months prior to screening and throughout the study.&#xD;
&#xD;
          -  On a stable treatment with an angiotensin converting enzyme (ACE) inhibitor or an&#xD;
             angiotensin receptor blocker, i.e., no change in dose regimen or in dose levels in the&#xD;
             last 4 weeks prior to screening and until randomization.&#xD;
&#xD;
          -  On a stable treatment with an ACE inhibitor or an angiotensin receptor blocker after&#xD;
             switching from beta-blockers and/or thiazides for eligible patients after screening,&#xD;
             i.e., no change in dose regimen and in dose levels in the last 4 weeks prior to run-in&#xD;
             phase and until randomization&#xD;
&#xD;
          -  Body weight between 50.0 kg and 130 kg, inclusive, if male, and between 40.0 kg and&#xD;
             110 kg, inclusive, if female, body mass index between 18.0 and 38.0 kg/m2, inclusive.&#xD;
&#xD;
          -  Kidney function: Estimated glomerular filtration rate at screening must be 60&#xD;
             mL/min/1.73m2 or higher.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients with severe anemia, severe cardiovascular, gastrointestinal, respiratory,&#xD;
             neurological, osteomuscular, psychiatric, or active malignant tumor or other major&#xD;
             systemic disease or patients with infectious disease, signs of acute illness, or short&#xD;
             life expectancy making implementation of the protocol or interpretation of the study&#xD;
             results difficult (as evaluated by detailed medical history and complete physical and&#xD;
             laboratory examination).&#xD;
&#xD;
          -  Heart failure New York Heart Association (NYHA) Classification III/IV.&#xD;
&#xD;
          -  Any clinically significant abnormality in echocardiography performed at screening as&#xD;
             judged by the investigator based on age, gender and medical history of the individual&#xD;
             patient.&#xD;
&#xD;
          -  History of myocardial infarction within the last 12 months prior to screening.&#xD;
&#xD;
          -  Likelihood of requiring treatment during the study period with drugs not permitted by&#xD;
             the study protocol (e.g., long-term systemic glucocorticoids) and refusing or unable&#xD;
             to take alternative treatment.&#xD;
&#xD;
          -  Type 1 diabetes mellitus.&#xD;
&#xD;
          -  Secondary hypertension of any etiology (eg, renovascular disease, pheochromocytoma,&#xD;
             Cushing's syndrome).&#xD;
&#xD;
          -  Clinically significant pulmonary hypertension, in particular World Health Organisation&#xD;
             (WHO) Classes IV (Pulmonary hypertension due to chronic thrombotic and/or embolic&#xD;
             disease [CTEPH]) and V (miscellaneous).&#xD;
&#xD;
          -  Diabetic retinopathy.&#xD;
&#xD;
          -  History of diabetic ketoacidosis or non-ketotic hyperosmolar coma within 12 weeks&#xD;
             prior to the Screening Visit.&#xD;
&#xD;
          -  History of severe hypoglycemia resulting in hospitalization or&#xD;
             unconsciousness/seizures within 6 months prior to the Screening visit.&#xD;
&#xD;
          -  History of prior gastric or intestinal surgical procedure including gastric banding&#xD;
             within 3 years before the Screening Visit. Any gastrointestinal surgery with removal&#xD;
             of part of the bowels or the stomach&#xD;
&#xD;
          -  History of unexplained pancreatitis, chronic pancreatitis, stomach/gastric surgery,&#xD;
             inflammatory bowel disease.&#xD;
&#xD;
          -  Known hypersensitivity to sotagliflozin, empagliflozin or any excipient of the drug&#xD;
             products.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 2760001</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

